scispace - formally typeset
G

Gordon Whiteley

Researcher at Leidos

Publications -  16
Citations -  3684

Gordon Whiteley is an academic researcher from Leidos. The author has contributed to research in topics: Proteomics & Proteogenomics. The author has an hindex of 14, co-authored 16 publications receiving 2646 citations.

Papers
More filters
Journal ArticleDOI

Proteogenomic characterization of human colon and rectal cancer

Bing Zhang, +64 more
- 18 Sep 2014 - 
TL;DR: Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.
Journal ArticleDOI

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

TL;DR: A view of how the somatic genome drives the cancer proteome and associations between protein and post-translational modification levels and clinical outcomes in HGSC is provided.
Journal ArticleDOI

Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach

TL;DR: A workshop was held at the National Institutes of Health with representatives from the multiple communities developing and employing targeted MS assays and defined three tiers of assays distinguished by their performance and extent of analytical characterization.
Journal ArticleDOI

Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.

Suhas Vasaikar, +82 more
- 02 May 2019 - 
TL;DR: Comparative proteomic and phosphoproteomic analysis of paired tumor and normal adjacent tissues produced a catalog of colon cancer-associated proteins and phosphosites, including known and putative new biomarkers, drug targets, and cancer/testis antigens, which suggested glycolysis as a potential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade.
Journal ArticleDOI

Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.

Karsten Krug, +94 more
- 25 Nov 2020 - 
TL;DR: The integration of mass spectrometry-based proteomics with next-generation DNA and RNA sequencing profiles tumors more comprehensively underscores the potential of proteogenomics for clinical investigation of breast cancer through more accurate annotation of targetable pathways and biological features of this remarkably heterogeneous malignancy.